Nicox SA

ALCOX

FR0013018124

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:35:08 2024-04-26 am EDT			5-day change	1st Jan Change
0.374 ^EUR	-0.27%		-1.84%	-15.38%

Apr. 22	Nicox: cash position of 9.1 million euros at the end of March	CF
Feb. 28	Nicox, BlackRock Sign Deal for Debt Restructuring	MT

Nicox S.A. Reports Earnings Results for the Half Year Ended June 30, 2023

October 20, 2023 at 09:26 am EDT

Nicox S.A. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported revenue was EUR 1.73 million compared to EUR 1.43 million a year ago. Net loss was EUR 6.61 million compared to EUR 17.01 million a year ago.

Latest news about Nicox SA

Nicox: cash position of 9.1 million euros at the end of March	Apr. 22	CF
Nicox, BlackRock Sign Deal for Debt Restructuring	Feb. 28	MT
Nicox Names Chief Business Officer as New CEO	Feb. 28	MT
Nicox SA Announces CEO Changes	Feb. 28	CI
Nicox, Kowa Team Up to Develop, Commercialize NCX 470 Eyedrop in Japan	Feb. 08	MT
Nicox to Receive US Patent Extension for Latanoprostene Bunod	Jan. 31	MT
Nicox SA Receives Confirmation of 5-Year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA	Jan. 31	CI
Nicox: sales up 29% in 2023	Jan. 25	CF
Nicox's Announces Publication of New Nonclinical Data Demonstrating More Effective Intraocular Pressure Lowering of NCX 470 Compared to Lumigan	Dec. 14	CI
Nicox S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-10-20	CI
Nicox: surrounded after market study	23-07-10	CF
Nicox's New Drug Application for Eye Drop Medicine Gets Priority Review Status in China	23-04-28	MT
Nicox Set for Euronext Growth Paris Transfer	23-04-26	MT
Nicox: new data on two compounds	23-04-26	CF
Nicox: Armistice Capital falls below 5% threshold	23-04-25	CF
Global markets live: ASML, Netflix, United Airlines, Morgan Stanley, Tesla...	23-04-19
Nicox: cash position shrinks, share price plummets	23-04-19	CF
Nicox Jumps 28% as Chinese Partner Files New Drug Application for Eye Drop	23-04-14	MT
Nicox: share price soars, progress on Zerviate in China	23-04-14	CF
Nicox SA Announces New Drug Application Submission for ZERVIATE in China	23-04-14	CI
Global markets live: UBS, Berkshire Hathaway, First Republic Bank, Goldman Sachs...	23-03-20
Nicox: reduced losses in 2022, but reduced cash flow	23-03-20	CF
Nicox S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-19	CI
Nicox: HBM Healthcare Investments falls below 5% threshold	23-01-23	CF
Nicox: cash position reassuring, but sales still limited	23-01-18	CF

Chart Nicox SA

Duration

Period

More charts

Company Profile

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The Company is also conducting research on NCX 1728 in retinal conditions. NCX 4251 for topical ocular application for dry eye disease is being developed by Nicox's licensed partner Ocumension Therapeutics in China and is available for partnering elsewhere. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow Health, Inc. in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets."

Sector

Pharmaceuticals

Calendar

2024-05-05 - Association for Research in Vision and Ophthalmology Meeting - Corinna Galli

More about the company

Income Statement Evolution

More financial data

Ratings for Nicox SA

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.374 EUR

Average target price

1 EUR

Spread / Average Target

+167.38%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
NICOX SA	-15.38%	19.97M
MERCK KGAA	+5.31%	70.44B
KYOWA KIRIN CO. LTD.	+10.97%	8.94B
SK BIOPHARMACEUTICALS CO., LTD.	-16.83%	4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+43.48%	4.5B
YUHAN CORPORATION	+3.20%	3.85B
INDIVIOR PLC	+18.82%	2.38B
BETTA PHARMACEUTICALS CO., LTD.	-21.36%	2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.67%	2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+8.38%	1.96B

Specialty & Advanced Pharmaceuticals

Nicox SA

Equities

ALCOX

FR0013018124

Pharmaceuticals

Nicox S.A. Reports Earnings Results for the Half Year Ended June 30, 2023

EPS Revisions